Vanda Pharmaceuticals Inc. Stock News

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment. The week's news w

WINTON GROUP Ltd reduced its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 13.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 70,292 shares of the biopharmaceutical companys stock after selling 11,286 shares during the quarter. WINTON GROUP Ltd []

Related Stocks: VNDA ,

Bank of America Corp DE raised its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 10.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 278,063 shares of the biopharmaceutical companys stock after buying an additional 25,551 shares during the quarter. Bank of []

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares, rose in value on Friday, 11/26/21, with the stock price down by -4.50% to the previous days close as strong demand from buyers drove the stock to $16.55. Actively observing the price movement in the last trading, the stock closed the session at $17.33, falling within a range of $16.36 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA): A Great Stock To Watch Read More »

UBS Asset Management Americas Inc. increased its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 16.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 47,841 shares of the biopharmaceutical companys stock after purchasing an additional 6,582 shares during the period. UBS Asset Management Americas Inc.s holdings in Vanda Pharmaceuticals were worth $1,029,000 as []

WASHINGTON, Nov. 10, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda management will participate at the following upcoming investor conferences in Nov

Vanda Pharmaceuticals (NASDAQ:VNDA) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Vanda Pharmaceuticals (NASDAQ:VNDA) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.

WASHINGTON, Oct. 27, 2021 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2021 on Wednesday, November 3, 2021, after t

WASHINGTON, Sept. 7, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the Citi 16th Annual BioPharma Virtual Conferen

Vanda (VNDA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear

WASHINGTON, Aug. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospital

Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2021 Results - Earnings Call Transcript